Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000702158 | SCV000830999 | uncertain significance | Imerslund-Grasbeck syndrome | 2018-06-14 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with CUBN-related disease. This variant is present in population databases (rs544059289, ExAC 0.01%). This sequence change replaces proline with leucine at codon 2243 of the CUBN protein (p.Pro2243Leu). The proline residue is weakly conserved and there is a moderate physicochemical difference between proline and leucine. |
Fulgent Genetics, |
RCV002477618 | SCV002788999 | uncertain significance | Imerslund-Grasbeck syndrome type 1; Proteinuria, chronic benign | 2022-04-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004026585 | SCV004854045 | uncertain significance | Inborn genetic diseases | 2024-01-23 | criteria provided, single submitter | clinical testing | The c.6728C>T (p.P2243L) alteration is located in exon 44 (coding exon 44) of the CUBN gene. This alteration results from a C to T substitution at nucleotide position 6728, causing the proline (P) at amino acid position 2243 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |